Skip to main
IMUX
IMUX logo

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Immunic Inc. is demonstrating promising advancements in its pipeline, particularly with IMU-856, which has shown a statistically significant increase in GLP-1 production in celiac disease patients, indicating potential for broader metabolic benefits. The drug's successful results and its readiness for Phase 2 development position it as a compelling candidate for addressing unmet needs in chronic inflammatory conditions, suggesting opportunities for strategic partnerships or financing. Furthermore, preclinical studies indicating a significant reduction in body weight gain linked to decreased food intake further support the positive outlook for IMU-856's efficacy and market potential.

Bears say

Immunic Inc faces significant risks that contribute to a negative outlook on its stock, primarily related to the potential failure of its developmental candidates to meet peak commercial revenue estimates, which could stem from limitations in market size, penetration rates, or pricing strategies. Additionally, the company's ability to secure adequate capital resources for ongoing operations is uncertain, raising concerns about its financial stability. Furthermore, the continuation of program development and successful commercialization remains in question, highlighting operational challenges that could hinder future growth prospects.

Immunic Inc (IMUX) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Buy based on their latest research and market trends.

According to 13 analysts, Immunic Inc (IMUX) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.